Clinical trials of disease-modifying agents in pediatric MS
Article 2019 en
Authors
EW
Emmanuelle Waubant
BB
Brenda Banwell
EW
Evangeline Wassmer
Abstract
1 min read
A primary goal is to ensure high-quality evidence-based treatment for children and adolescents with MS, which will improve our understanding of the safety of these agents and remove regulatory or insurance-based limitations in access to treatment.
Se Jin Park, Hyo Soon An, Sung Hye Kim, Seong Heon Kim, Heeyeon Cho, Jae Hyun Kim, Anna Cho, Ji Hee Kwak, Jae Il Shin, Keum Hwa Lee, Jin-Hee Oh, Jung Won Lee, Hae Soon Kim, Hye-Jung Shin, Mi Young Han, Myung Chul Hyun, Tae‐Sun Ha, Young Hwan Song
Robert Zivadinov, Anthony T. Reder, Massimo Filippi, Alireza Minagar, Olaf Stüve, Hans Lassmann, Michael K. Racke, Michael G. Dwyer, Elliot M. Frohman, Omar Khan
Massimo Filippi, Maria Pia Amato, Diego Centonze, Paolo Gallo, Claudio Gasperini, Matilde Inglese, Francesco Patti, Carlo Pozzilli, Paolo Preziosa, María Trojano
Discussion(0)
No comments yet. Be the first to comment.